Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α) pathway protect ovarian cancer cells from metformin-induced apoptosis
Authors:
- 7 February 2015
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 55 (4) , 346-356
Abstract
Metformin, an oral biguanide for the treatment of type II diabetes, has been shown to have anticancer effects in ovarian cancer. Energy starvation induced by metformin causes endoplasmic reticulum stress-mediated unfolded protein response (UPR) and autophagy. UPR and autophagy act as a survival or death mechanism in cells. In this study, we observed that metformin-induced apoptosis was relieved by autophagy and the PERK/eIF2α pathway in ovarian cancer cells, but not in peripheral blood mononuclear cells (PBMC) or ‘normal’ ovarian surface epithelial cells (OSE). Increased PARP cleavage and increased LC3B-II with ATG5-ATG12 complex suggested the induction of apoptosis and autophagy, respectively, in metformin-treated ovarian cancer cells. Accumulation of acidic vacuoles in the cytoplasm and downregulation of p62 further supported late-stage autophagy. Interestingly, metformin induced interdependent activation between autophagy and the UPR, especially the PERK/eIF2α pathway. Inhibition of autophagy-induced PERK inhibition, and vice versa, were demonstrated using small molecular inhibitors (PERK inhibitor I, GSK2606414; autophagy inhibitor, 3-MA, and BafA1). Moreover, autophagy and PERK activation protected ovarian cancer cells against metformin-induced apoptosis. Metformin treatment in the presence of inhibitors of PERK and autophagy, however, had no cytotoxic effects on OSE or PBMC. In conclusion, these results suggest that inhibition of autophagy and PERK can enhance the selective anticancer effects of metformin on ovarian cancer cells.Keywords
Funding Information
- National Research Foundation of Korea (2009-0093820, 5256-20140100)
This publication has 40 references indexed in Scilit:
- Metformin—mode of action and clinical implications for diabetes and cancerNature Reviews Endocrinology, 2014
- Metformin intake is associated with better survival in ovarian cancerCancer, 2012
- Metformin targets ovarian cancer stem cells in vitro and in vivoGynecologic Oncology, 2012
- Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and ChemosensitivityObstetrics & Gynecology, 2012
- Cellular and molecular mechanisms of metformin: an overviewClinical Science, 2011
- Use of metformin and the risk of ovarian cancer: A case–control analysisGynecologic Oncology, 2011
- Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteinsGynecologic Oncology, 2011
- Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In VivoNeoplasia, 2011
- Metformin attenuates ovarian cancer cell growth in an AMP‐kinase dispensable mannerJournal of Cellular and Molecular Medicine, 2011
- In vitro metformin anti-neoplastic activity in epithelial ovarian cancerGynecologic Oncology, 2008